Blue Horseshoe Stocks: BVTK Pops Again & More

Bravatek Solutions, Inc. BVTK

BVTK was among our mentions in Wednesday’s premarket report after it was unearthed in our chatroom* the previous morning before making a 500% move.  Those who missed that run got another chance right away as the stock ran from .0009-.0035 that afternoon, and topped out at .0041 to close out the short week on Friday. That added another two-day swing of 355% to the activity we had observed in BVTK, which was followed by a pullback to .0015.

Once again, to kick off the new trading week yesterday, BVTK began to run, returning to a high of .0034 on the day, representing yet another two-day upswing out of this volatile runner amounting to 127%  The stock ended the session having traded roughly three-and-a-half times its monthly average volume. Things could get very interesting if it can manage to crack resistance at the previous swing high of .0041.

The company filed an 8-K this morning as well , pertaining to an agreement with i3 Integrative Creative Solutions, pursuant to which i3 Integrative will promote and solicit commitments in the United States federal government military and civilian markets regarding the Company’s cybersecurity email software and telecom services. (>>View Filing)

*We encourage all of our readers to join in on our daily in-session live chats. To participate, simply create/sign into your Skype account and send a contact request to ‘stocksumo’.



Bank of America Corp BAC – Options Ideas 

Whenever we spot an opportunity to swoop in post-earnings with some options ideas, we jump on it right away, and that’s what we have with BAC this morning.

We haven’t highlighted this stock in quite awhile,but with a very solid beat on earnings and a small gap-up in the premarket, we’re going to want to signal a couple of short term contracts for observation in the BAC Weekly $22.50 and $23 Calls.

In the event that a more sustained rebound is in the cards, considering the fact that BAC was already coming off of a relative bottom just yesterday, we’ll have the BAC 05/12 $23.50 & $24 Calls on watch as well.



Bottom-Watchlist

We want to put an observational tag on both Sorrento Therapeutics, Inc. SRNE and OncoMed Pharmaceuticals, Inc. OMED.  Both of these stocks have taken serious beatings of late, and consequently, are in extreme oversold territory. Chances for recovery plays here seem quite high, so we’re going to watch for these to establish higher lows in sessions ahead.


Extended Watchlist:
JAMN, MYDX, CAB, SSYS, BIOC, NFLX

TSLA, PLUG, ETRM, OMED & Extended Watchlist

Tesla Motors, Inc. TSLA – Options
-
Back on November 29th, we were noticing that conditions on the TSLA chart had been exhibiting signs of a coming uptrend, and as a result, we presented a few options trading ideas that we felt had a reasonable chance of success. In particular, the 12/21 $120 Calls, and the 12/27 $130 Calls. We were rewarded for our interest, as the stock did indeed find its legs and begin to run following that report.

Since then we’ve seen some major moves out of those contracts, as the $120 Calls ended up trading from a low of 8.40, all the way up to yesterday’s closing price of 25.46, a monstrous 203% gain. The $130 Calls saw their low at 5.03, and ended up closing at 17.07. That was good for an even larger 239% rip.

Chartwise, it appears as if resistance is sitting at $145.65, $151, and the 50DMA of $159.45, and there is a gap on the chart to fill from $160-176, so a push past those key resistance points could lead to more pronounced increases. We would continue to take advantage of the added gains on these contracts, and in the event of a sustained uptrend, would have to consider rolling our strike price up to higher level that we believe would still be pushed into the money.


Plug Power, Inc. PLUG

PLUG has been an old favorite of ours from last March when we caught it on our scanners coming off its 52-wk lows (.1155) and we’ve mentioned it on multiple occasions since that time. We’ve followed this play all the way up to current levels, which as a result of recent favorable reports on the company’s finances, have reached all the way up to this morning’s pre-market high of 1.41. That represents an increase of 1121% off of lows following our initial alert.

We’ll be continuing to monitor PLUG closely, and will certainly want to take part in today’s conference call/webcast in which the CEO will address the reasoning behind his statement that the company is on pace for a “blowout quarter.”, as well as other issues.

LATHAM, N.Y., Dec 04, 2013 (GLOBE NEWSWIRE via COMTEX) — Plug Power Inc. (Nasdaq:PLUG), a leader in providing clean, reliable energy solutions, will today host a conference call and webcast during which CEO Andy Marsh will provide a business update for Plug Power and the Company’s expectations for the remainder of 2013 and for 2014.Since the October 8 business update call, the Company has seen an additional 17.8M USD in bookings. Plug Power is currently in negotiations with several large customers on sales agreements to deploy turn-key GenDrive solutions at multiple distribution centers. The Company believes this will significantly impact the fourth quarter bookings, as well as provide a recurring revenue stream from product, service and hydrogen contracts. Plug Power expects orders to range between 30M and 40M USD for the fourth quarter of 2013.

Plug Power has scheduled its conference call and webcast today at 10:30 am ET to review the Company’s business updates. Participants are encouraged to join the webcast to access the accompanying slide show presentation. The webcast can be accessed by going directly to the Plug Power Web site (www.plugpower.com) and selecting the webcast link on the home page. You can also call-in by dialing 877.407.8291. Andy Marsh will be joined by COO, Keith Schmid, and Vice President of Sales, Erik Hansen, to answer questions.


EnteroMedics, Inc. ETRM

ETRM was part of yesterday’s Extended Watchlist, and the stock went on to put up quite a performance. After touching a low of 1.48 shortly before 10:30am, ETRM would spend the rest of the day pressing upward to its high of day and closing price at 2.24. This marks an impressive intraday run of 51% on nearly 20x its 3mo. average volume.

We’ll certainly want to keep an eye on a stock with current momentum of this magnitude.


OncoMed Pharmaceuticals, Inc. OMED

Another winner from yesterday’s Extended Watchlist, OMED traded in a range from 22.10-31.99, which marks an intraday move of 45% Quite an impressive feat for a big-board stock in this price range.

Congrats to anyone who caught this, or any of the opportunities for significant profits afforded by the excellent calls in yesterday’s report.


Extended Watchlist:
IACH, BLDP, FCEL, CCXI, ABIO, IMMU, CPST, RAD, ICLD, CYTR,
HEM (Recently coming off 52week lows),
OCLS (FDA Approval news out this am)

CNAT, GOGO, UNIS, CAMT & Extended Watchlist

Conatus Pharmaceuticals, Inc. CNAT

We caught CNAT on our scanner this morning, and is definitely a stock we’d like to keep an eye on today, following an FDA-related announcement regarding a drug that the company has under development receiving “Orphan Drug” status. FDA plays have provided us with countless opportunities in the past, especially when the news is untraded upon, so we’ll be interested to see how well CNAT fares today as a result.

SAN DIEGO, Dec. 2, 2013 (GLOBE NEWSWIRE) — Conatus Pharmaceuticals Inc. (CNAT), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus’ drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA’s Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.

Conatus is developing emricasan, a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death (or apoptosis), for the treatment of patients with chronic liver disease and significant unmet medical need.


GOGO, Inc. GOGO

We have been hot on the trail of GOGO since our first mention on Monday Sept. 16th when it was trading as low as 14.79. We witnessed the stock’s 52-wk high a few weeks later on Nov. 14th (31.55), and then it consolidated to find support at 24.24.

Yesterday, GOGO re-established its 52-wk high at 31.65, and appears to want to gap up and continue its run today. This morning, the company has news out concerning the green light is has received to install its wifi satellite technology on Boeing 747 aircraft. and we’ve seen pre-market trades going off as high as 32.75. From our original alert price, that marks registers as a 121% gain. Heading into today’s session, we’d like to see the previous 52-wk high of 31.55 hold as support on any future pullbacks.

ITASCA, Ill., Dec. 2, 2013 /PRNewswire via COMTEX/ — Gogo (NASDAQ: GOGO), the world leader of in-flight connectivity and a pioneer in wireless in-flight digital entertainment solutions, passed a key milestone in launching its international connectivity service by receiving an STC to install its Ku-satellite technology on Boeing 747-400 aircraft.

Gogo will begin testing the new service immediately and plans to offer the service for customer usage by the first quarter of 2014. The technology will give travelers and crew access to the Internet. The service will also offer passengers Gogo Vision, Gogo’s wireless in-flight entertainment service.


Unilife Corp. UNIS

UNI hits our radar screens as another play with fresh news and a chart that is gapping up premarket. UNIS has a potentially lucrative arrangement in the works with European Pharma giant, Novartis.

YORK, Pa., Dec. 2, 2013 /PRNewswire/ – Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS, ASX: UNS) today announced an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with one of Novartis’ targeted early-stage pipeline drugs.

Under this agreement, Unilife will supply Novartis with a customized delivery device, consisting of syringe, needle, tubing, controller and pump, to enable administration of a novel investigational Novartis drug into a targeted organ in clinical trials. Unilife has granted Novartis an option for exclusivity under this agreement.



Camtek, Ltd. CAMT

Yesterday wasn’t the first time we’ve mentioned CAMT on our extended watchlist only to see the stock turn in an impressive performance; last Monday, we tagged CAMT as a possible runner, and subsequently witnessed a pop from 4.11-5.29 (+29%). In a repeat of that scenario, yesterday we saw the stock trade from a low of 4.20 on up to 5.75, for a possible gain of 37%

Cheers to anyone who was able to take advantage of those very timely alerts!


Extended Watchlist:
IACH, OMED, ETRM, FRO, DGLY, NAVB